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ADVANCING CELLULAR
and IMMUNE-BASED
CANCER THERAPIES

Scott Waldman, MD, PhD and
Adam Snook, PhD are developing a
vaccine to fight colorectal cancer.

6

New Colorectal Cancer Vaccine

THE NCI-DESIGNATED SIDNEY KIMMEL CANCER CENTER (SKCC)
is the heart of Jefferson’s broad-based cancer
research program. SKCC investigators are
currently pursuing hundreds of basic science,
translational and clinical studies on cancer cell
biology and signaling, molecular biology and
genetics, and specific diseases ranging from
brain cancer to uveal melanoma. Among the
most exciting efforts are partnerships between
SKCC basic scientists and clinician-researchers
to both advance new immune-based therapies
and continuously improve current approaches.
Glioblastomas are aggressive brain tumors—and
very hard to eliminate completely. However, a
glioblastoma combination immunomodulatory
vaccine approach developed by Jefferson
researchers is now progressing into a phase II trial.
The immunomodulatory vaccine product is notable
for its initial success with a tumor type where
previous immunotherapy approaches have failed.
Created by David Andrews, MD, professor of
neurosurgery, and D. Craig Hooper, PhD, professor
of cancer biology, the vaccine employs a patient’s
own tumor cells collected during surgical removal
of the primary brain tumor. The researchers treat
those cells with an antisense oligodeoxynucleotide
(AS-ODN) containing immunostimulatory motifs.
The AS-ODN works against a receptor shown to
drive tumor growth and metastasis and the activity of
tumor-promoting, anti-inflammatory macrophages.
Next, the cells are loaded into a dime-sized
diffusion chamber with additional AS-ODN, and
the contents are irradiated. The chamber is then
implanted under the patient’s skin, allowing antigens
produced by the cells and the AS-ODN to diffuse
into the body to stimulate pro-inflammatory tumorimmune cells and boost anti-tumor immunity.
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A new Jefferson-developed colorectal cancer
vaccine also shows great promise. The adenovirus
vector vaccine works by prompting an immune
response specifically to a colorectal cancer tumor
antigen called guanylyl cyclase (GUCY2C), first
identified by Scott Waldman, MD, PhD, Samuel M.V.
Hamilton Professor of Medicine. Developed by Dr.
Waldman and Adam Snook, PhD, assistant professor
of pharmacology and experimental therapeutics,
the vaccine combines a GUCY2C molecule with
a molecule that boosts the anti-tumor activity of
CD8 positive cytolytic T lymphocytes. GUCY2C
is expressed by cells lining the intestine and by at
least several types of cancer cells; but, because
the vaccine is injected into arm muscle, it does not
come into contact with healthy intestinal cells.
In a phase I clinical trial, patients’ blood showed
markers of immune activation, suggesting that the
vaccine could train the immune system to attack
colon cancer cells that had spread before surgical
removal. In pre-clinical mouse studies, the vaccine
reduced the formation of colon cancer metastases
in the lungs by >99% percent and more than
doubled survival time. The researchers—who are
preparing for phase II trials of the vaccine—recently
found that GUCY2C is also expressed by gastric,
esophageal and pancreatic cancer cells. They will
pursue opportunities to test the vaccine with those
cancers as well.
GUCY2C is also the target of a new CAR-T-based
immunotherapy for colorectal cancer that Drs. Snook
and Waldman have developed. The therapy—which
engineers and re-infuses patients’ own immune
cells to target only the tumor—is preparing to enter
phase I trials. Previously, a human-ready version of
the therapy proved successful in killing tumors and
preventing metastatic growth in mice—more than
quintupling survival in cases with advanced lung
metastases. Notably, there were no off-target or
adverse effects of the treatment, which has been a
major problem for other CAR-T cancer therapies.
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Two-Step Approach
A unique approach to bone marrow transplant
(BMT) involving half-matched (haploidentical) donors
and higher-risk patients has proven as effective
as transplants that use traditional, fully-matched
donors. And continuing improvements in the
procedure are driving even better results for patients.
The “two-step approach”—developed by Neal
Flomenberg, MD, professor of medical oncology—
has been used in more than 300 procedures
involving half-matched donors since 2006.
Until recently, Jefferson was the only institution
in the nation using the two-step approach.
In traditional BMT, chemotherapy (and, sometimes, radiation therapy) is administered before
the patient receives an infusion containing both
T-cells and stem cells in a single step; then
immunosuppressive drugs are used to prevent
or limit the otherwise overwhelming immune
response that results in graft-versus-host disease
(GVHD). In the two-step approach, after half
the chemotherapy is administered, just donor
T-cells are infused; two days later, the remaining
chemotherapy is administered. (As a result, the
cells spurring GVHD are eliminated, which lessens
the need for a close HLA match.) Finally, an
infusion of highly purified stem cells is given.
The two-step approach’s benefits for patients are
significant: less-aggressive regimes of immunesuppressant drugs; reduced incidence of GVHD;
and engraftment of donor cells that occurs more
quickly than with a traditional approach. Perhaps most
significantly, the process and time needed to find a
donor are reduced—a huge factor since approximately
only 30 percent of patients will have a family member
who is a full match. In addition, Dr. Flomenberg’s
approach gathers donor cells differently: rather
than extracting stem cells from bone marrow,
they are harvested from the donor’s blood. It is
less painful and less risky for donors, and enables
the physicians to better standardize the number
of cancer-fighting T-cells and stem cells (which
replenish depleted blood supply) given the patient. 

The glioblastoma and colorectal cancer vaccines reflect one
facet of Jefferson’s expansive basic science and translational
research on vaccines. See Vaccines Fighting Viruses and
Cancer on page 18 for a broader look at that work.
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